YAKHAK HOEJI

Table. 2.

Table 2 Current policies on the expansion of drug indications in Australia, the UK, and Japan

Country	Pricing	Risk Sharing Agreement	Negotiation	Post market management	Contract renewal cycle
Korea	Negotiation based on economic evaluation at initial listing & indication expansion	Financial risk: price discounting, rebate, subsidization	O	• Monitoring volume • Volume-based pricing	5 years
Australia		• Financial risk: rebate, subsidization cap • Clinical risk: managed access contract		Monitoring volume by indication using unique code	5 years
The United kingdom				• Monitoring volume by indication • VPAS	3 years
Japan	• Formula • Reference pricing • Frequent repricing	Financial risk: price discounting based on budget impact	X	Monitoring annual expenditure	Until price discounting